Inclisiran

Inclisiran, sold under the brand name Leqvio, is a medication for the treatment of people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk equivalents and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA that inhibits translation of the protein PCSK9.[5][6][7][2] Inclisiran was approved for use in the European Union in December 2020.[4] In August 2021, it received NIC... [wikipedia]